Ningbo MedicalSystem Biotechnology Co Ltd (300439) - Total Assets
Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) holds total assets worth CN¥3.66 Billion CNY (≈ $534.88 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Ningbo MedicalSystem Biotechnology Co Lt (300439) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Ningbo MedicalSystem Biotechnology Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Ningbo MedicalSystem Biotechnology Co Lt for net asset value and shareholders' equity analysis.
Ningbo MedicalSystem Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Ningbo MedicalSystem Biotechnology Co Ltd's total assets of CN¥3.66 Billion consist of 49.2% current assets and 50.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.7% |
| Accounts Receivable | CN¥572.72 Million | 15.5% |
| Inventory | CN¥286.01 Million | 7.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥135.43 Million | 3.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ningbo MedicalSystem Biotechnology Co Lt market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ningbo MedicalSystem Biotechnology Co Ltd's current assets represent 49.2% of total assets in 2024, a decrease from 61.8% in 2011.
- Cash Position: Cash and equivalents constituted 19.7% of total assets in 2024, up from 19.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Ningbo MedicalSystem Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A
|
Germany | €17.91 Billion |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
BGI Genomics Co Ltd
SHE:300676
|
China | CN¥11.35 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
Brazil | R$3.03 Billion |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Immunovia publ AB
ST:IMMNOV
|
Sweden | Skr65.70 Million |
Ningbo MedicalSystem Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.12 | 3.07 | 1.13 |
| Quick Ratio | 2.70 | 2.62 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.28 Billion | CN¥1.21 Billion | CN¥180.40 Million |
Ningbo MedicalSystem Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Ningbo MedicalSystem Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.36 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 6.2% |
| Total Assets | CN¥3.71 Billion |
| Market Capitalization | $480.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ningbo MedicalSystem Biotechnology Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ningbo MedicalSystem Biotechnology Co Ltd's assets grew by 6.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual total assets of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.71 Billion ≈ $542.17 Million |
+6.19% |
| 2023-12-31 | CN¥3.49 Billion ≈ $510.58 Million |
-2.64% |
| 2022-12-31 | CN¥3.58 Billion ≈ $524.40 Million |
-0.26% |
| 2021-12-31 | CN¥3.59 Billion ≈ $525.80 Million |
+10.42% |
| 2020-12-31 | CN¥3.25 Billion ≈ $476.19 Million |
-13.01% |
| 2019-12-31 | CN¥3.74 Billion ≈ $547.41 Million |
-18.62% |
| 2018-12-31 | CN¥4.60 Billion ≈ $672.69 Million |
+7.44% |
| 2017-12-31 | CN¥4.28 Billion ≈ $626.09 Million |
+25.17% |
| 2016-12-31 | CN¥3.42 Billion ≈ $500.20 Million |
+136.26% |
| 2015-12-31 | CN¥1.45 Billion ≈ $211.71 Million |
+132.89% |
| 2014-12-31 | CN¥621.25 Million ≈ $90.91 Million |
+31.92% |
| 2013-12-31 | CN¥470.92 Million ≈ $68.91 Million |
+42.17% |
| 2012-12-31 | CN¥331.23 Million ≈ $48.47 Million |
+84.88% |
| 2011-12-31 | CN¥179.16 Million ≈ $26.22 Million |
-- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more